Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity‐Related Genes
- 10 February 2026
- journal article
- Published by Wiley in Pediatric Obesity
- Vol. 21 (2) , e70091
Abstract
Objectives: To evaluate the impact of semaglutide on body mass index (BMI) and cardiometabolic markers in adolescents with obesity and genetic variants associated with monogenic or syndromic obesity. Methods: A retrospective chart review was conducted in adolescents with severe obesity who underwent multigene panel testing and were treated with semaglutide. Results: Twenty‐seven adolescents (mean age 15 ± 1.9 years); BMI % of the 95th percentile 158 ± 29; (70% White) were treated with semaglutide for a mean of 10 ± 4.7 months. Participants were classified into three groups: (1) Dominant or Known Risk Variants ( n = 7); (2) Carriers of Rare Variants in Recessive Genes ( n = 10); and (3) Negative or Unmatched Genetic Findings ( n = 10). All groups showed reductions in BMI, which was not different between the groups. Adolescents with dominant or known risk variants experienced a significant decrease in BMI % of the 95th percentile (−17, (IQR −26 to −10) p = 0.022) and in BMI by −9.4% ± 7% ( p = 0.035). Significant improvements in median non‐HDL cholesterol (−16 mg/dL), total cholesterol (−15 mg/dL), and HbA1c (−0.3%) were noted in children with dominant or known risk variants ( p = 0.036). Conclusions: Semaglutide was associated with significant reductions in BMI and cardiometabolic markers in adolescents (majority White) with dominant or known risk variants for monogenic obesity.Keywords
This publication has 22 references indexed in Scilit:
- Prevalence of genetic causes of obesity in clinical practiceObesity Science & Practice, 2023
- Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-AnalysisThe Journal of Pediatrics, 2021
- Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor AgonistCell Metabolism, 2018
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiencyMolecular Metabolism, 2017
- The Limitations of Transforming Very High Body Mass Indexes into z -Scores among 8.7 Million 2- to 4-Year-Old ChildrenThe Journal of Pediatrics, 2017
- Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor systemInternational Journal of Obesity, 2017
- Functional and clinical relevance of novel and known PCSK1 variants for childhood obesity and glucose metabolismMolecular Metabolism, 2017
- BMI z‐Scores are a poor indicator of adiposity among 2‐ to 19‐year‐olds with very high BMIs, NHANES 1999‐2000 to 2013‐2014Obesity, 2017
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- The Relationship of Health Outcomes to Improvement in BMI in Children and AdolescentsObesity Research, 2005